Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Ribasphere® Receives FDA Approval for Use in HCV Patients
 

Three Rivers Pharmaceuticals recently announced U.S. Food and Drug Administration (FDA) approval for its Ribasphere® (ribavirin, USP) Tablets 600 mg, 400 mg, and 200 mg in combination with interferon alfa-2a for the treatment of hepatitis C (HCV).

While interferon plus ribavirin combination therapy is commonly used in HCV patients, this new FDA approval offers potential benefits such as improved efficacy and better patient adherence to treatment. “Ribasphere® Tablets 600 mg, 400 mg, and 200 mg provide the patient and physician an opportunity to significantly reduce the number of tablets a patient has to take each day,” said Three Rivers President and CEO Donald J. Kerrish, R.Ph. “Three Rivers believes that this has the potential to lead to better patient compliance and improved patient outcomes.”

Three Rivers, which is based Cranberry Township, PA, will market and distribute the product with it’s partner PAR Pharmaceuticals of Spring Valley, NY.

Source: Three Rivers Pharmaceuticals press release dated December 5, 2005

 

This section of our Web site is sponsored by: